CASI News and Press, CASI Pharmaceuticals Inc. From 08/10/20

CASI Pharmaceuticals, Inc. (CASI) Q2 2020 Results Conference Call August 10, 2020 04:30 PM ET Company Participants Cynthia Hu - General Counsel & Secretary Dr. Wei-Wu He - Chairman and CEO Dr. Alex Zukiwski - Chief Medical Officer Conference Call Participants Nathaniel ...

CASI Pharmaceuticals (NASDAQ: CASI ) : Q2 GAAP EPS of -$0.09 misses by $0.01 . More news on: CASI Pharmaceuticals, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, , Read more ...

ROCKVILLE, Md. and BEIJING , Aug. 10, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results and business highligh...

ROCKVILLE, Md. and BEIJING , Aug. 3, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the Company will host a conference...

Deals and Financing Beijing's BeiGene (NSDQ: [[BGNE]]; HK: 06160) in-licensed Greater China rights to three inhibitors for chronic hepatitis B virus ((HBV)) from Assembly Biosciences (NSDQ: [[ASMB]]) in a $540 million agreement. All three molecules have started US clinical trials. BeiGen...

CASI Pharmaceuticals (NASDAQ: CASI ) is up 11.9% after hours following news that its Chairman/CEO, Wei-Wu He, bought nearly $7.9M worth of the company's stock. More news on: CASI Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more ...

CASI Pharmaceuticals ( CASI -12.3% )   prices its public offering of 20M at $1.90/share, for gross proceeds of $38M. More news on: CASI Pharmaceuticals, Inc., Healthcare stocks news, , Stocks on the move, Read more ...

ROCKVILLE, Md. and BEIJING , July 22, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced the pricing of an underwritten publi...

CASI Pharmaceuticals (NASDAQ: CASI )   -10.3%  AH  announced that it has commenced an underwritten public offering to issue and sell shares of its common stock with a 30-day underwriter option to purchase up to an additional 15% of the shares. More news on: CASI Pharmaceut...

ROCKVILLE, Md. and BEIJING , July 21, 2020 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced that it has commenced an underwritte...